, /PRNewswire/ -- Aspen Neuroscience will present this week to a global audience of clinicians, regulators, researchers, technologists and industry partners at the 2024 annual meeting of the International Society for Cell & Gene Therapy (ISCT) in , . "We are excited to be part of this meeting, which covers the latest advancements in cell and gene therapy," commented Aspen Chief Executive Officer Damien McDevitt, PhD. "The members of the ISCT community share our vision to translate the potential of cell and gene therapies into safe and effective medicines to improve patients' lives.
" As part of the ISCT 2024 Translational Pathway Sessions, as well as the ISCT main program, Chief Scientific Officer , Ph.D., and Chief Technology Officer will discuss developments in autologous research and development, including for ANPD001, autologous iPSC-derived neuron replacement therapy currently under investigation for Parkinson's disease in a Phase 1/2a clinical trial, as well as advancements in manufacturing of autologous iPSCs.
Daniel Fremgen, Director of Analytical Development, will present regarding analytical development strategy including machine learning genomic models and characterization of autologous iPSCs and dopaminergic neuron precursor cells. The Aspen Neuroscience schedule of presentations includes: Headquartered in , Aspen Neuroscience, Inc. is a clinical development-stage, private company focused on autologous regenerative medicine.
The company's patient-derived iPSC platf.
